Martine Zimmermann insider trades: Ligand Pharmaceuticals (LGND) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Martine reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | LGND | ↓ Sell | 1,200 | $285.00 | $342K | Direct | Sep 14, 2026 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About Martine Zimmermann's insider trades
Martine Zimmermann is a director at Ligand Pharmaceuticals (LGND). Since Sep 10, 2026, Martine has reported no open-market purchases and 1 sale worth $342K on SEC Form 4. In the last 12 months: 1 sale ($342K).
Their filings also include shares withheld for taxes (4 filings), grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.